Pharmacy Practice and Administration Presentations (UMKC)The items in this collection are the scholarly output of the faculty, staff, and students of the Division of Pharmacy Practice and Administration.https://hdl.handle.net/10355/92242024-03-28T14:03:14Z2024-03-28T14:03:14ZAn Electro-magnetic cell stimulator [abstract]Rizk, Hatem IbrahimMo, Cheng L.Leon-Salas, Walter D. (Walter Daniel)Hall, ToddWacker, Michael J.Brotto, Marcohttps://hdl.handle.net/10355/54742017-03-21T18:03:14Z2010-03-01T00:00:00ZAn Electro-magnetic cell stimulator [abstract]
Rizk, Hatem Ibrahim; Mo, Cheng L.; Leon-Salas, Walter D. (Walter Daniel); Hall, Todd; Wacker, Michael J.; Brotto, Marco
A device to stimulate bone and muscle cell growth and possibly for treatment of bone and muscle injuries is presented. The device, called EStim, generates electric and magnetic pulses at programmable intervals. This device will also be used to study the crosstalk between bone and muscle cell growth. In a human or animal body, muscles and bones are intimately interrelated and the loss of activity in one of them affects the other. This interrelation is especially evident in persons with bone fractures. While the bone is healing, the muscles loose mass due to lack of exercise. Furthermore, when skeletal muscles are not exercised, bone mass decreases. In these situations, muscle mass can be partially maintained if externally stimulated by applying repetitive electric pulses. The EStim has been designed to generate electric pulses of different frequencies and amplitudes to stimulate muscle growth. It also generates magnetic pulses to stimulate bone growth. This dual stimulation is a unique feature of the EStim and makes it a promising device in the treatment of bone fractures or for muscle stimulation. Besides this clinical application, the EStim is being used to study the crosstalk at the cellular level between muscle and bone cells. A line of C2C12 cells is being used to test the effects of the electric and magnetic pulses on cell growth. Variables such as pulse repetition, field strength and rest period duration have been evaluated. Initial results show that electric stimulation induces cell hypertrophy similar to the ones observed in heat shock experiments (see abstract by Romero et al). The EStim device consists of three sections: the controller, the high-voltage generation unit and the high-current generation unit. The controller is built around the MSP430 low-power microcontroller. It handles communication with a host computer to change settings or to perform tests. Settings such as pulse repetition, pulse width, number of pulses, rest time between pulses, and magnetic field strength can be changed by the user. The controller also monitors the battery voltage and the maximum pulse current. As a safety measure, pulse generation is stopped if the current through the probe exceeds a preset value. The high-voltage generation unit consists of a boost converter that is able to generate voltages up to 40 V and an H-bridge that allows the generation of biphasic or monophasic electric pulses. The high-current unit consists of a buck converter able to generate currents up to 10 A. These large currents are used to generate magnetic fields of up to 10 mT. This device will be used to better understand the interplay between bones and muscles. Ultimately, our goal is test this device in animals and humans to fully realize its applications on musculoskeletal injuries and diseases.
Biomedical Tissue Engineering, Biomaterials, and Medical Devices Poster Session
2010-03-01T00:00:00ZSmart Cardiovascular Stent against In-Stent RestenosisAssel, ThomasCuddalore, ChetanLeon-Salas, Walter D. (Walter Daniel)Lee, Chi H. (Chi-Hyun)https://hdl.handle.net/10355/54902017-03-21T18:03:15Z2010-03-01T00:00:00ZSmart Cardiovascular Stent against In-Stent Restenosis
Assel, Thomas; Cuddalore, Chetan; Leon-Salas, Walter D. (Walter Daniel); Lee, Chi H. (Chi-Hyun)
A smart cardiovascular stent to be used as a single set of theranostics (therapeutics and diagnostics) is developed. The stent is aimed at delivering nitric oxide as a therapeutic agent and monitoring stent-induced restenosis. This novel approach is intended to reduce the risks stemmed from implanted stents and lowering manufacturing cost. The proposed stent will provide a non-invasive and continuous monitoring of restenosis caused by the stent. To assess the level of restenosis, pressure and blood flow will be monitored inside the blood vessel where the stent is placed. Existing techniques that employ catheters to measure pressure inside blood vessels are not suitable because they are too invasive, cannot monitor pressure for long periods of time and restrict the patient to be in a hospital setting. Our approach consists of two miniature pressure sensors and a small microchip incorporated into the stent. The pressure sensors are placed at the opposite sides of the stent. Blood flow is obtained by assessing the pressure difference at these two points. The microchip reads out the pressure sensors outputs and wirelessly transmits them to a reader outside the body. Due to size constraints and safety reasons a battery cannot be used as a power source for the microchip. Instead, power is provided from the reader via electromagnetic coupling. In order to reduce the number of components to be implanted, we are proposing to employ the stent body not only as a mechanical supporter but also as an antenna. To provide an optimal power match between the microchip and the antenna, the impedance of the stent was fully characterized. This characterization has been performed using computer simulations of five different commercially available stent designs. It was found that at the frequencies of interest (902 to 928 MHz) the impedance is highly reactive. To compensate for the reactive impedance of the antenna, a matching network was designed. A prototype microchip with different components has been designed and is currently being fabricated. Future work includes micro-assembly of a prototype stent for the collection of pressure measurements using an aortic bifurcation model. Once completed, this stent will be useful in monitoring the level of restenosis and will lower the risks presented by implantable stents.
Jump Starting Technologies, Patent Issues, & Translational Medicine Poster Session
2010-03-01T00:00:00ZA Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV InfectionHarper, Diane MedvedHarris, George D.Shaffer, Todd D.Gabriel, MichelleHoffmann-LaRocheSantee, Jenniferhttps://hdl.handle.net/10355/63502017-03-21T18:06:19Z2010-03-01T00:00:00ZA Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection
Harper, Diane Medved; Harris, George D.; Shaffer, Todd D.; Gabriel, Michelle; Hoffmann-LaRoche; Santee, Jennifer
This is a randomized, double blind, placebo controlled, parallel group multicenter study in women with biopsy confirmed Grade 2 or Grade 3 cervical intraepithelial neoplasia (CIN). Two hundred patients will be enrolled and randomized in a 2: 1 ratio of RO5217790: placebo. They will be stratified on the basis of their HPV genotyping with stratum 1 consisting of those women with HPV 16 single infection and stratum 2 consisting of those with single or multiple infections with other high risk genotypes. Three injections of RO5217790 (5 x 107pfu) will be administered subcutaneously, each one week apart. Interim colposcopy, cytology and HPV assessments will be performed at Month 3. All patients will undergo conization at Month 6. The primary endpoint is histologic response at Month 6 in HPV 16 single infected patients, as assessed by central pathology review. The secondary endpoints include histologic response in all CIN2/3 patients enrolled regardless of genotype, viral clearance, safety, and immune response (cellular and humoral). After the Month 6 conization, the study will be unblinded and patients will undergo follow-up for an additional 2 years for efficacy and safety. This includes visits at Months 12, 18, 24 and 30 to assess histologic relapse/recurrence and viral re-infection as well as reporting of any serious adverse events. An interim analysis will be conducted when a minimum of 80 patients (at least 20 of whom have single infection with HPV 16 and 20 of whom have infection with HPV 16 plus HPV 16 related genotypes) have undergone conization. NCT01022346
Comparative Medicine - OneHealth and Comparative Medicine Poster Session
2010-03-01T00:00:00Z